DUBLIN--(BUSINESS WIRE)--The "Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. A detailed picture of the Paroxysmal ...

A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...

Please provide your email address to receive an email when new articles are posted on . A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated ...

Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...

A nasal spray containing the investigational calcium channel blocker etripamil is efficacious and safe in patients with paroxysmal supraventricular tachycardia, topline results suggest. The RAPID ...

Photo Credit: AHA/Scott Morgan 2022. Used with permission. CHICAGO, IL—Full results of the RAPID trial testing etripamil nasal spray for patients with paroxysmal supraventricular tachycardia (PSVT) ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has received FDA approval for its first commercial product, CARDAMYST nasal spray, for the conversion of acute symptomatic episodes of paroxysmal ...

Since the stock-jolting phase III blowup in March of Milestone Pharmaceuticals Inc.’s etripamil for paroxysmal supraventricular tachycardia (PSVT), questions have lingered regarding the short-acting ...